441 related articles for article (PubMed ID: 34489572)
21. PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors.
Videira A; Beckedorff FC; daSilva LF; Verjovski-Almeida S
Cell Commun Signal; 2021 Jan; 19(1):5. PubMed ID: 33430890
[TBL] [Abstract][Full Text] [Related]
22. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
[TBL] [Abstract][Full Text] [Related]
23. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.
Davies A; Zoubeidi A; Selth LA
Endocr Relat Cancer; 2020 Feb; 27(2):R35-R50. PubMed ID: 31804971
[TBL] [Abstract][Full Text] [Related]
24. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.
Stelloo S; Bergman AM; Zwart W
Endocr Relat Cancer; 2019 May; 26(5):R267-R285. PubMed ID: 30865928
[TBL] [Abstract][Full Text] [Related]
26. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
[TBL] [Abstract][Full Text] [Related]
27. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C
Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846
[TBL] [Abstract][Full Text] [Related]
28. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
29. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth.
Mygatt JG; Singhal A; Sukumar G; Dalgard CL; Kaleeba JA
Cancer Res; 2013 Sep; 73(18):5695-708. PubMed ID: 24005834
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
32. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
Pomerantz MM; Li F; Takeda DY; Lenci R; Chonkar A; Chabot M; Cejas P; Vazquez F; Cook J; Shivdasani RA; Bowden M; Lis R; Hahn WC; Kantoff PW; Brown M; Loda M; Long HW; Freedman ML
Nat Genet; 2015 Nov; 47(11):1346-51. PubMed ID: 26457646
[TBL] [Abstract][Full Text] [Related]
33. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
[TBL] [Abstract][Full Text] [Related]
35. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
37. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.
Eickhoff N; Bergman AM; Zwart W
Endocrinology; 2022 Oct; 163(11):. PubMed ID: 36125208
[TBL] [Abstract][Full Text] [Related]
38. Novel lncRNA
Lingadahalli S; Jadhao S; Sung YY; Chen M; Hu L; Chen X; Cheung E
Mol Cancer Res; 2018 Dec; 16(12):1865-1878. PubMed ID: 30115758
[TBL] [Abstract][Full Text] [Related]
39. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.
Nyquist MD; Li Y; Hwang TH; Manlove LS; Vessella RL; Silverstein KA; Voytas DF; Dehm SM
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17492-7. PubMed ID: 24101480
[TBL] [Abstract][Full Text] [Related]
40. Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.
Fong KW; Zhao JC; Kim J; Li S; Yang YA; Song B; Rittie L; Hu M; Yang X; Perbal B; Yu J
Cancer Res; 2017 Jan; 77(2):412-422. PubMed ID: 27815387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
